Background: Type 2 diabetes includes a series of disorders characterized by hyperglycemia, which are followed by dysfunction in insulin secretion. In the clinical laboratory, A1C test defines blood glucose levels over a three-month period. The aim of this study is to evaluate the correlation between HbA1c and hyperlipidemia in patients with type 2 diabetes.
Materials and Methods: An cross-sectional study was performed on 209 diabetic patients men (n=109) and women (n=100) with a mean age of 57.1 ± 11.1 years. Diagnosis of diabetes was performed according to the WHO criteria. In this study, venous blood (5 ml) was collected from participants after overnight fasting, and HbA1C levels and lipid profiles were determined using enzymatic methods and auto-analyzer device. Risk factor values (TCH/HDL-C) and atherogenic index of plasma (AIP) (logTG/HDL-c), as well as LDL-C/HDL-C ratio, were calculated.
Results: HDL-C and TCH / HDL-C were significantly increased in women. On the other hand, LDL-C/HDL-C and HbA1c levels were significantly higher in men. There was no significant difference in the levels of cholesterol, triglyceride, fast blood sugar (FBS), LDL-C, and AIP between women and men. Cholesterol, FBS, LDL-C and LDL-C/HDL-C also showed a significant direct correlation with HbA1c, but no significant correlation was observed between triglyceride, HDL, AIP, and risk ratio with HbA1c.
Conclusion: HbA1c may be considered as a biomarker for dyslipidemia screening in patients with type 2 diabetes
Association AD. Standards of Medical Care in Diabetes—2014. Diabetes Care 2014; 37 (Suppl. 1): S14–S80Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2014; 37 (Suppl. 1): S81–S90. Diabetes care. 2014;37(3):887-.
Hasan Z, Zia S, Maracy M. Baseline disease knowledge assessment in patients with type 2 diabetes in a rural area of northwest of Pakistan. JOURNAL-PAKISTAN MEDICAL ASSOCIATION. 2004;54(2):67-72.
Rani HS, Madhavi G, Rao VR, Sahay B, Jyothy A. Risk factors for coronary heart disease in type II diabetes mellitus. Indian journal of clinical biochemistry. 2005;20(2):75-80.
Ebrahimi-Far M, Mazdapour M, Kaki A, Mohammadi P, Zakerjafari M, Lavi A ea. Comparison of Biochemical Factors and Liver Enzymes in type 2 Diabetes Patients and Healthy Individuals. . Bull EnvPharmacol Life Sci. 2015;4(01-4).
Federation I. International Diabetes Federation: IDF Diabetes Atlas. Brussels, Belgium. 2013.
Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A1c in the management of diabetes. Journal of diabetes. 2009;1(1):9-17.
Hasanvand B, Karami K, Khodadi A, Valipour M. Impact determination of strength and resistance training on Glycoside hemoglobin and blood sugar on patients with type II diabetes”. Yafteh. 2011;13(3):75-81.
Karamati M, Sadeghyan M, Parezadeh M, F M. Relation between glycolyted hemoglobin and blood cholesterol in patient with type II diabete. Medical Journal of Mashhad University of Medical Sciences. 2008;5(3):159-64.
Kennel WB, DL M. Diabetes and cardiovascular disease: the framingham study. JAMA 1979.241:2035-8.
Carmena R. High risk of lipoprotein dysfunction in type 2 diabetes mellitus. Revista Española de Cardiología. 2008;8(Supl. C):18-24.
Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405-12.
Robinson D, Luthra M, Vallis M. Canadian diabetes association clinical practice guidelines expert committee. Canadian diabetes association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2013;37(suppl 1):S1-S212.
SALEHIN S, AZIZIMOGHADAM A, AMIRSHAHI M, ABDOLLAHIMOHAMMAD A. A STUDY ON CORRELATION BETWEEN GLYCOSYLATED HEMOGLOBIN, BODY MASS INDEX, DISEASE DURARUION, INSULIN DOSAGE AND MENSTRUAL DURATION IN TYPE 1 DIABETIC ADOLESCENTS. 2013.
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus.. Nat Rev Dis Primers. 2015;1(15019).
Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes care. 2005;28(3):514-20.
Erciyas F, Taneli F, Arslan B, Uslu Y. Glycemic control, oxidative stress, and lipid profile in children with type 1 diabetes mellitus. Archives of medical Research. 2004;35(2):134-40.
Dr. Haider Mohammed Fayyad Alyasiri, Dr.AliAbidSadoon, Dr.KadhimMohan. RELATIONSHIPBETWEENHBA1CAND HYPERLIPIDAEMIAINPATIENTSWITH DIABETESMELLITUS. Thi-QarMedicalJournal(TQMJ). 2012;6(1):67-71.
Rosediani M, Azidah A, Mafauzy M. Correlation between fasting plasma glucose, post prandial glucose and glycated haemoglobin and fructosamine. The Medical journal of Malaysia. 2006;61(1):67-71.
Samatha P, Prabodh V, Chowdary N, Shekhar R. Glycated hemoglobin and serum lipid profile associations in type 2 diabetes mellitus patients. J Pharmac Biomed Sci. 2012;17(17):1-4.
Hussain A, Ali I, Ijaz M, Rahim A. Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. Therapeutic advances in endocrinology and metabolism. 2017;8(4):51-7.
Dr.RajulLodha, Dr.Renuka Z Lal, Dr.ShwetaBiyani. HbA1c as screening biomarker of dyslipidemia in Type 2 Diabetes mellitus patients. Sch J App Med Sci. 2016;4(5C):1600-2.
Bodhe C, Jankar D, Bhutada T, Patwardhan M, Patwardhan V. HbA1c: predictor of dyslipidemia and atherogenicity in diabetes mellitus. International Journal of Basic Medical Sciences and Pharmacy (IJBMSP). 2012;2(1).
Parsanasab H, Moradi Pudeh B, Alizadeh A, Abediankenari S. Evaluation of correlation between HbA1c with the Risk factors of lipid profile in patients with type 2 diabetes. Journal of Mazandaran University of Medical Sciences. 2013;22(2):153-6.
Khan H, Sobki S, Khan S. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA 1c predicts dyslipidaemia. Clinical and experimental medicine. 2007;7(1):24-9.